NCT Number: NCT04706962
Phase: PHASE1
Trial Summary: Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts:
Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refr – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Theratechnologies
Acronym: